News from MHRA – read the article here
The MHRA is the latest regulator to join the Australia-Canada-Singapore-Switzerland (ACSS) Consortium.
The aim of the consortium is to provide patients with timely ‘access’ to high quality, safe and effective therapeutic products across the five countries.
The MHRA is one of the world’s leading regulators of therapeutic products, and they will bring additional resources and expertise to the well-established collaboration group.
The MHRA will officially commence working with Consortium partners as a full member from the 01 January 2021 with a period of shadowing before then.